House of Commons photo

Track Colin

Your Say

Elsewhere

Crucial Fact

  • His favourite word is oshawa.

Conservative MP for Oshawa (Ontario)

Won his last election, in 2021, with 40% of the vote.

Statements in the House

Canada Consumer Product Safety Act April 29th, 2009

Mr. Speaker, I want to thank the hon. member for all his help and good work on the health committee.

I believe, as I think he does, that the committee gets to choose which witnesses it would like to bring forward. With any type of legislation it is very important to this government and all members of the House to entertain the opinions of all stakeholders who have an interest in the legislation.

The idea here, on which I think everyone in the House would agree, is that the health and safety of Canadians is very important. Canadians have to have confidence in their government and confidence in consumer products. The legislation on the books now is from the 1960s. It is time we modernized it. We live in a new global framework.

I look forward to the bill going to committee. I know we will be working diligently to bring forward good legislation for the Canadian people.

Canada Consumer Product Safety Act April 29th, 2009

Mr. Speaker, I am pleased to speak in support of Bill C-6. This proposed legislation delivers on the Government of Canada's commitment to improve protection for Canadian consumers through stronger product safety laws. Canadians should be confident in the quality and safety of the products they buy.

The proposed Canada consumer product safety act would modernize our system by raising the bar for industry and by improving protection of the public against the few who would act irresponsibly.

Most Canadian companies manufacture, import and sell safe products and yet, some high-profile safety issues related to consumer products have caused concern among Canadians. These include lead found in imported children's toys and small, powerful magnets found in a variety of children's products that have been known to break off and can then be swallowed by a child. Those incidents highlighted the need to improve consumer product legislation.

This proposed legislation addresses the need to modernize part I of the Hazardous Products Act, an act that has not been amended since its introduction in the late 1960s. Much has changed in the past four decades. Globalization has meant that many consumer goods available in Canada are now manufactured in countries with lower standards for consumer health and safety. Technology has also had an impact. Many of today's consumer goods contain elements and compounds unheard of 40 years ago. So, over time, the safety net that Canadian consumers have come to expect is not as broad as it could or should be.

Allow me to detail a few of the gaps that exist in the current Hazardous Products Act.

It contains no general prohibition against supplying unsafe consumer products that pose an unreasonable danger. It provides only limited authority to detect and identify unsafe products at an early stage. It does not allow government to respond rapidly to unregulated products or hazards. It does not contain the power for government to recall flawed products when a company is unco-operative or slow in doing so.

In short, the existing act needs to be strengthened. Bill C-6, the proposed Canada consumer product safety act, would do just that.

The proposed new act would make it an offence to supply products that pose an unreasonable danger to human health or safety. It would expand the scope of legislation to cover the manufacture of consumer products. It would introduce mandatory reporting of incidents, requiring industry to report when it has knowledge of a serious accident or incident, even if that incident has not caused harm. This would provide an early warning mechanism to allow government to act.

The proposed new act would give the government the authority to require manufacturers and importers to provide results from tests or studies on products. Packaging or labels on products which are false, misleading or deceptive as they relate to health or safety would be prohibited under the proposed legislation. It would require industry to keep detailed records so products could be traced through their supply chain.

The proposed legislation would also introduce an order power so inspectors could require suppliers to recall or take other corrective measures, as well as to take quick action when the supplier failed to do so.

Finally, the proposed act seeks to put in greater deterrents. Fines and penalties would be significantly increased. Maximum fines of up to $5 million would be in place for some offences, while others would have a maximum that would be left to the court's discretion.

We believe these provisions would give Canadian consumers the protection they deserve and expect when they purchase goods ranging from toys to household goods.

There are several groups of consumer products that are regulated by other acts and would not be subject to the proposed legislation. For example, natural health products, which are regulated by a section of the Food and Drugs Act, would not be subject to this proposed legislation. Some stakeholders have expressed confusion about this. As a result, the Minister of Health has written the chair of the health committee to inform her that our government would be moving forward with an amendment to this bill, making it clear that this proposed legislation would not affect natural health products.

Coupled with other initiatives under the food and consumer safety action plan, this proposed act seeks to provide Canadians with a comprehensive scheme for safer consumer products, responsible suppliers across the board and better informed consumers.

This government takes consumer safety seriously and we are taking action. Canadians look to the federal government to show leadership in enhancing the safety of consumer products in this new global marketplace and we are responding.

This proposed new legislation has been developed in consultation with numerous stakeholders and also reflects input made during the discussion on former Bill C-52 in the second session of the 39th Parliament. After 40 years, it brings Canadian consumer protection up to date and provides the same level of protection enjoyed by residents of other countries.

As well, by raising the strength of our product safety system up to the level of our major trading partners, we are safeguarding our marketplace against the risk of becoming a dumping ground for substandard products.

The lowest price can be alluring for consumers and even more so in tough economic times. As a result, we can expect industry to cut corners where it can. Bill C-6 would help prevent any shortcuts on safety. We need the improvements proposed in Bill C-6 now more than ever before.

With the support of members of the House, consumers and businesses will reap the benefits. We have created the ideal package of consumer protection by combining measures to improve prevention, monitor high risk products and act swiftly if a dangerous product enters the supply chain.

Canadians deserve to have confidence when they buy products at their local store. I trust that all members will agree and will join us in supporting Bill C-6.

Canada Consumer Product Safety Act April 29th, 2009

Mr. Speaker, if you seek it, I think you will find unanimous consent that I share my time with the member for Kenora.

Motions for Papers April 29th, 2009

Mr. Speaker, I ask that all notices of motions for the production of papers be allowed to stand.

Questions on the Order Paper April 29th, 2009

Mr. Speaker, I ask that all questions be allowed to stand.

Human Pathogens and Toxins Act April 22nd, 2009

Madam Speaker, I thank the hon. member for the NDP for her statement, but I would like to take this opportunity to compliment all members of the health committee.

This very important legislation is much overdue. There are over 4,000 laboratories in Canada that right now work with human pathogens. We need to ensure that we know where these pathogens and toxins are.

We had some excellent witnesses. We had great government witnesses and very good private witnesses. Each member of the health committee worked very hard to get proper input, not only the NDP but the Liberals, the Bloc Québécois and the Conservative Party.

I take this opportunity to thank all my colleagues on the health committee for being so helpful in getting this very important legislation put through.

Human Pathogens and Toxins Act April 22nd, 2009

Madam Speaker, we tried to make the amendments and the language very consistent, which was already passed in the House with the human reproduction act. Therefore, the answer to the member's question is that the minister will act appropriately when she brings these things forward.

Human Pathogens and Toxins Act April 22nd, 2009

Madam Speaker, I am pleased to rise today at report stage of Bill C-11, An Act to promote safety and security with respect to human pathogens and toxins, to speak to the government amendments to clauses 66.1 and 66.2, which are now before us.

We heard at second reading that there is strong support in this House for strengthening safety and security with regard to human pathogens and toxins right here in Canada. We are committed to moving forward with this legislation to address the serious safety and security gaps that we have identified in order to safeguard Canadians from the threats posed by human pathogens and toxins.

Members of the Standing Committee on Health had an extensive opportunity to review all elements of Bill C-11. All told, the committee heard from five government witnesses, in some cases more than once, and from 13 other witnesses over a period of a month. In total there were seven separate sessions devoted almost entirely to review and discussion of Bill C-11. In these sessions, all voices were heard and all opinions were closely considered. The result of the committee's hard work is an amended bill that we think well reflects the underlying policy intent of the bill, as well as other key aspects of concern to some witnesses.

There were 12 amendments to the bill, of which eight were put forth by the government and four were put forth by the opposition. These amendments include a government amendment to clarify technical aspects of the bill, such as the fact that there will be no requirement to report to the minister of health when there is a simple spill in the laboratory, but only when there is a release of a human pathogen or toxin from the facility itself.

As well, two opposition amendments were put forward to require the establishment of scientific advisory committees to advise the minister of health regarding the schedules to the bill. These amendments, which the government supports, go a long way in ensuring there is an evidence base for decision-making on how to treat dangerous, and less dangerous, pathogens.

Two other government amendments responded to input that the committee received from the office of the Privacy Commissioner, which we believe resulted in better privacy protection in this bill.

The bill was also amended to clearly articulate that there will be no security screening of persons accessing risk group 2 human pathogens and to signal that the regulations should be drafted taking into account the varying degrees of risk between risk groups of human pathogens and between toxins. As well, the penalty clauses in Bill C-11 were amended to lower the penalties related to contraventions of the act and regulations related to risk group 2 human pathogens.

These amendments were made to respond to what we heard from numerous witnesses at committee who strongly emphasized that risk group 2 human pathogens, although clearly capable of causing serious disease and death, posed lesser risks. Therefore they warranted less stringent treatment both in the bill and in the regulations.

We heard what these witnesses had to say and the government was comfortable proposing these numerous amendments which were all agreed to at committee.

In addition to the successful amendments put forward at committee, two amendments are related to a requirement for the tabling of regulations made under Bill C-11 before both Houses of Parliament. These amendments were put forward by the opposition and became the new clauses 66.1 and 66.2. They were agreed to by the committee, including the government members, subject to one qualification.

The government responded to these proposed amendments by requesting that the words “and the Senate” be added where the words “House of Commons” appeared in the amendments, to ensure that the regulations would also be tabled there.

After some discussion, the committee agreed to the suggestion, which was considered a friendly amendment, with agreement that the changed amendments would be worded in a way similar to what is now found in the Assisted Human Reproduction Act.

Unfortunately, upon review of the bill as reported from the Standing Committee on Health, it became obvious that this last specific requirement relating to the tabling of regulations in both Houses of Parliament was not included in the amended bill, as was requested by the committee.

Many of the needed references to the Senate, and particularly the fact that the regulations must be referred to a committee of that House, were simply left out. The government has put forward amendments at report stage to address this omission.

More specifically, the government has proposed an amendment to clause 66.1 to require that the regulations be tabled before each House of Parliament and that a proposed regulation that is laid before Parliament shall be referred to the appropriate committee of each House, as determined by the rules.

The new clause 66.2 allows for some specific exemptions from the requirement to table regulations in both houses of Parliament. The proposed government amendment now before us specifies that should the Minister of Health make a regulation without first laying it before either house of Parliament, she must lay before each house a statement of reasons for doing so.

These proposed government amendments to clauses 66.1 and 66.2 are completely in line with the wordings of section 66 and 67 of the Assisted Human Reproduction Act as requested and agreed to by the Standing Committee on Health.

The bill, with these new amendments, reflects the hard work and co-operative approach that was taken at committee, reflecting the need to work together to safeguard the health and safety of Canadians. I would like to take this opportunity to thank the members of the committee for a job well done.

I request that the House agree to these amendments, which simply reflect what the committee had previously agreed was the right way to proceed, in the same spirit of co-operation and concern for the health and safety of Canadians that was apparent in all of the discussions around Bill C-11 that occurred in committee.

As I noted, we believe that the amended Bill C-11, which was reported to the House from committee, is a stronger piece of legislation that well reflects the policy intent of the legislation and concerns expressed by some witnesses at committee. These government amendments to clauses 66.1 and 66.2 will essentially complete the good work of the committee by ensuring that the amended Bill C-11 reflects what was actually agreed to by committee in consideration of the input of many witnesses over a period a month.

Canada-Peru Free Trade Agreement Implementation Act April 20th, 2009

Mr. Speaker, I listened intently to the member's speech. He seems to be missing some of the historic points about free trade agreements. Free trade agreements tend to raise the GDP of both countries involved, increase trade of both countries, and raise the economic status of individual workers in both countries.

Canada has a duty to help increase the rights of citizens around the world and lead by example. One of the best ways is through economic engagement. Canada needs new trading partners, not fewer.

The member seems to infer that Canadian companies would take advantage of foreign workers. I find that quite insulting, because Canadian companies are some of the most ethical companies around the world and they have a history of leading by example. They raise human rights and wages for the general population around the world through economic engagement.

This is a great opportunity for Canadians and Canadian companies. My NDP colleague does not seem to understand that the future is in greater access to foreign markets, not less.

I wonder if he could answer the question, what does the NDP have against quality Canadian companies and Canadian entrepreneurs who want to help improve the lives of workers around the world through economic engagement? We have a great history of that. Why does he think this would be different at this stage?

Autism April 2nd, 2009

Mr. Speaker, I would like to thank the hon. member for her question and I would like to thank the member for Edmonton—Mill Woods—Beaumont for his hard work and commitment to autism advocacy.

Our government recognizes that autism is an important health and social issue that presents challenges for many Canadian families. I am pleased to inform the House that our government has declared April 2 as Autism Awareness Day in Canada. Better knowledge about autism is essential to family service providers and policy makers. I can assure the House that our government is showing leadership by focusing our attention on building the autism evidence base so that future action by our partners will be well informed.

I strongly believe that through our contributions and by working with our partners, we can enhance Canada's capacity—